

# Erratum: Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI

Isabelle Mahé<sup>1,2,3</sup> Ismaïl Elalamy<sup>3,4,5</sup> Grigoris T. Gerotziafas<sup>6,7</sup> Philippe Girard<sup>3,8</sup>

<sup>1</sup> Université de Paris, Innovations Thérapeutiques en Hémostase, INSERM, Paris, France

<sup>2</sup> Service de médecine Interne, AH-HP, Hôpital Louis Mourier, Colombes, Université de Paris, France

<sup>3</sup> F-CRIN INNOVTE, Saint Etienne, France

<sup>4</sup> Hematology and Thrombosis Center, Tenon University Hospital, Sorbonne University, INSERM U938, Paris, France

<sup>5</sup> Department of Obstetrics and Gynecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia

<sup>6</sup> Research Group “Cancer, Haemostasis and Angiogenesis,” INSERM UMR\_S 938, Centre de Recherche Saint-Antoine, Faculty of Medicine, Institut Universitaire de Cancérologie, Sorbonne Universities, Paris, France

<sup>7</sup> Service d’Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires de l’Est Parisien, APHP.6, Paris, France

<sup>8</sup> Institut du Thorax Curie-Montsouris, l’Institut Mutualiste Montsouris, Paris, France

Address for correspondence Isabelle Mahé, MD, PhD, Assistance Publique Hôpitaux de Paris, Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, France (e-mail: isabelle.mahe@aphp.fr).

TH Open 2019;3:e348–e349.

## ERRATUM

It has been brought to the publisher’s attention, that there was an error in Table 1 of the above article, published in *TH Open*, Volume 3, Number 3, 2019, pages e309–e315 (DOI: 10.1055/s-0039-1696659). In the SELECT-D study, it should state “N = 406” instead of “N = 203”.

The correct table appears below.

**Table 1** Protocol design of randomized control trials on anticoagulants for the treatment of cancer-associated thrombosis

Study (year)	Study drug/comparator	Patients	Methods/statistics	Primary endpoint	Secondary endpoints	Duration (mo)
ONCENOX <sup>39</sup> N = 122 (2006)	Enoxaparin/ warfarin	Active cancer, acute symptomatic VTE	Pilot feasibility	VTE recurrence	Major and minor bleeding	6
CANTHANOX <sup>25</sup> N = 146 (2002)	Enoxaparin/ warfarin	Active or treated cancer, PE, and/or DVT	S	Composite of major bleeding or recurrent VTE	Recurrent VTE Major bleeding	3
CLOT <sup>26</sup> N = 672 (2003)	Dalteparin/ warfarin	Active cancers, acute proximal symptomatic DVT or PE	Phase III/S	Symptomatic recurrence of DVT, PE, or both	Major bleeding Any bleeding	6
LITE CANCER <sup>27</sup> N = 200 (2006)	Tinzaparin/ warfarin	Cancer, acute proximal DVT	Phase III/S	Recurrent VTE or death	Major and minor bleeding	3
CATCH <sup>22</sup> N = 900 (2015)	Tinzaparin/ warfarin	Active cancers, acute proximal symptomatic DVT or PE	Phase III/S	VTE recurrence: proximal DVT, PE either symptomatic or incidental	Major bleeding CRNMB	6
SELECT-D <sup>23</sup> N = 406 (2018)	Rivaroxaban/ dalteparin	All active cancers, proximal DVT, PE, incidental PE	Pilot	VTE recurrence: proximal DVT, PE either symptomatic or incidental, and other sites	Major bleeding CRNMB	6
HOKUSAI-VTE Cancer <sup>21</sup> N = 1,046 (2018)	Edoxaban/ dalteparin	Active or history of cancer, acute symptomatic or incidental VTE	Phase III/NI	Composite of VTE recurrence (symptomatic or incidental) or major bleeding	VTE recurrence Major bleeding CRNMB	12
CARAVAGGIO <sup>35</sup> N = 1,168 (2019)	Apixaban/ dalteparin	Active or history of cancer, symptomatic or incidental proximal DVT or PE	Phase III/NI	Symptomatic or incidental VTE recurrence	Major bleeding	6

Abbreviations: CRNMB, clinically relevant nonmajor bleeding; DVT, deep-vein thrombosis; NI, noninferiority trial; PE, pulmonary embolism; S, superiority trial; VTE, venous thromboembolism.